180 related articles for article (PubMed ID: 29951517)
1. Anti-diabetic agents and heart health: how to use new diabetes medications in a global strategy for the prevention of cardiovascular complications in type 2 diabetes.
Gazzaruso C; Coppola A; Montalcini T; Falcone C
Ann Transl Med; 2018 May; 6(10):195. PubMed ID: 29951517
[No Abstract] [Full Text] [Related]
2. Cardiovascular safety of anti-diabetic drugs.
Kumar R; Kerins DM; Walther T
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
[TBL] [Abstract][Full Text] [Related]
3. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
Coccheri S
Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes--impact on adherence.
Sapkota S; Brien JA; Greenfield J; Aslani P
PLoS One; 2015; 10(2):e0118296. PubMed ID: 25710465
[TBL] [Abstract][Full Text] [Related]
5. The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications.
Oh TJ
J Obes Metab Syndr; 2019 Sep; 28(3):158-166. PubMed ID: 31583380
[TBL] [Abstract][Full Text] [Related]
6. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes.
Yaribeygi H; Atkin SL; Pirro M; Sahebkar A
J Cell Physiol; 2019 Jun; 234(6):8286-8294. PubMed ID: 30417367
[TBL] [Abstract][Full Text] [Related]
7. WITHDRAWN: Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus.
Fuller J; Stevens LK; Chaturvedi N; Holloway JF
Cochrane Database Syst Rev; 2007 Jul; (4):CD002188. PubMed ID: 17636699
[TBL] [Abstract][Full Text] [Related]
8. [Polish Multicenter Study on Diabetes Epidemiology (PMSDE)--1998-2000].
Szybiński Z
Pol Arch Med Wewn; 2001 Sep; 106(3):751-8. PubMed ID: 11928582
[TBL] [Abstract][Full Text] [Related]
9. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
10. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
Fonarow GC
Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
[TBL] [Abstract][Full Text] [Related]
11. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study.
Karlsson SA; Hero C; Svensson AM; Franzén S; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Eliasson B; Andersson Sundell K
BMJ Open; 2018 Mar; 8(3):e020309. PubMed ID: 29602853
[TBL] [Abstract][Full Text] [Related]
12. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
Deferrari G; Ravera M; Deferrari L; Vettoretti S; Ratto E; Parodi D
J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S224-9. PubMed ID: 12466318
[TBL] [Abstract][Full Text] [Related]
13. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
Packer M
Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
[TBL] [Abstract][Full Text] [Related]
14. Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
Bethel MA; Califf RM
Am J Cardiol; 2007 Mar; 99(5):726-31. PubMed ID: 17317381
[TBL] [Abstract][Full Text] [Related]
15. [New antidiabetic medications: at the dawn of a revolution? New therapeutic options for type 2 diabetes are challenged for cardiovascular disease prevention].
Crenier L
Rev Med Brux; 2016; 37(4):349-355. PubMed ID: 28525236
[TBL] [Abstract][Full Text] [Related]
16. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.
Patel VB; Parajuli N; Oudit GY
Clin Sci (Lond); 2014 Apr; 126(7):471-82. PubMed ID: 24329564
[TBL] [Abstract][Full Text] [Related]
17. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of the diabetic heart.
Tziakas DN; Chalikias GK; Kaski JC
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S3-S10. PubMed ID: 16340402
[TBL] [Abstract][Full Text] [Related]
19. Nepalese patients' anti-diabetic medication taking behaviour: an exploratory study.
Sapkota S; Brien JE; Aslani P
Ethn Health; 2018 Oct; 23(7):718-736. PubMed ID: 28277019
[TBL] [Abstract][Full Text] [Related]
20. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain.
Larrañaga I; Arteagoitia JM; Rodriguez JL; Gonzalez F; Esnaola S; Piniés JA;
Diabet Med; 2005 Aug; 22(8):1047-53. PubMed ID: 16026371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
